TR199800792T2 - CRF reseptör antagonistleri olarak pirazolopirimidinler. - Google Patents

CRF reseptör antagonistleri olarak pirazolopirimidinler.

Info

Publication number
TR199800792T2
TR199800792T2 TR1998/00792T TR9800792T TR199800792T2 TR 199800792 T2 TR199800792 T2 TR 199800792T2 TR 1998/00792 T TR1998/00792 T TR 1998/00792T TR 9800792 T TR9800792 T TR 9800792T TR 199800792 T2 TR199800792 T2 TR 199800792T2
Authority
TR
Turkey
Prior art keywords
alkyl
alkyloxy
alkylthio
cycloalkyl
mono
Prior art date
Application number
TR1998/00792T
Other languages
English (en)
Inventor
Chen Chen
R. Webb Thomas
R. Mccarthy James
J. Moran Terence
M. Wilcoxen Keith
Huang Charles
Original Assignee
Janssen Pharmaceutica N.V.
Neurocrine Biosciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V., Neurocrine Biosciences Inc. filed Critical Janssen Pharmaceutica N.V.
Publication of TR199800792T2 publication Critical patent/TR199800792T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Bu bulus, CRF reseptör antagonist özelliklerine sahip formül (I)e sahip bilesikler, bunlarin stereoizomerleri ve farmasötik açidan kabul edilebilir asit katilma tuzu sekilleri ile ilgili olup, burada R1, NR4R5 veya OR5 dir; R2, C1-6 alkil, C1-6 alkiloksi veya C1-6 alkiltiodur; R3, hidrojen, C1-6 alkilsülfonil, C1-6 alkilsülfoksi veya C1-6 alkiltiodur; R4, hidrojen, C1-6 alkil, mono-veya di (C3-6 sikloalkil)metil, C3-6 sikloalkil, C3-6 alkenil, hidroksi C1-6 alkil, C1-6 alkil-karboniloksi C1-6 alkil veya C1-6 alkiloksi C1-6 alkildir; R5, C1-8 alkil, mono-veya di (C3-6 sikloalkil) metil, Ar1CH2, C1-6 alkiloksi C1-6 alkil, hidroksi C1-6 alkil, C3-6 alkenil, tienil-metil, furanilmetil, C1-6 alkiltio C1-6 alkil, morfolinil, mono- veya di (C1-6 alkil) amino C1-6 alkil, di (C1-6 alkil) amino, C1-6 alkilkarbonil C1-6 alkil, imidazolil ile sübstitüe edilmis C1-6 alkil; veya -Alk-O-CO-Ar1 formülüne sahip bir radikaldir; veya R4 ile R5 bagli olduklari asot atomu ile birlikte (DEVAMI VAR).
TR1998/00792T 1996-02-07 1997-01-30 CRF reseptör antagonistleri olarak pirazolopirimidinler. TR199800792T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1127996P 1996-02-07 1996-02-07
US2768896P 1996-10-08 1996-10-08

Publications (1)

Publication Number Publication Date
TR199800792T2 true TR199800792T2 (tr) 1998-07-21

Family

ID=26682204

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/00792T TR199800792T2 (tr) 1996-02-07 1997-01-30 CRF reseptör antagonistleri olarak pirazolopirimidinler.

Country Status (27)

Country Link
EP (1) EP0880523B1 (tr)
JP (2) JP3356291B2 (tr)
KR (1) KR100421626B1 (tr)
CN (1) CN1090189C (tr)
AR (1) AR008577A1 (tr)
AT (1) ATE336495T1 (tr)
AU (1) AU713673B2 (tr)
BG (1) BG102349A (tr)
BR (1) BR9707391A (tr)
CA (1) CA2233285C (tr)
CZ (1) CZ244598A3 (tr)
DE (2) DE880523T1 (tr)
DK (1) DK0880523T3 (tr)
EA (1) EA000803B1 (tr)
EE (1) EE04282B1 (tr)
ES (1) ES2168237T3 (tr)
HU (1) HUP9900575A3 (tr)
ID (1) ID15905A (tr)
IL (1) IL123835A0 (tr)
NO (1) NO310292B1 (tr)
NZ (1) NZ330119A (tr)
PL (1) PL191271B1 (tr)
PT (1) PT880523E (tr)
SK (1) SK106398A3 (tr)
TR (1) TR199800792T2 (tr)
TW (1) TW449599B (tr)
WO (1) WO1997029109A1 (tr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124289A (en) * 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
AU747708B2 (en) * 1996-07-24 2002-05-23 Du Pont Pharmaceuticals Company Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US7094782B1 (en) 1996-07-24 2006-08-22 Bristol-Myers Squibb Company Azolo triazines and pyrimidines
DK0920429T3 (da) 1996-08-06 2003-05-12 Pfizer Substituerede pyrido- eller pyrimidoholdige, 6,6- eller 6,7-bicykliske derivater
US5723608A (en) * 1996-12-31 1998-03-03 Neurogen Corporation 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
JP2001511813A (ja) 1997-02-18 2001-08-14 ニューロクライン バイオサイエンシーズ，インコーポレイテッド Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法
US6235741B1 (en) * 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
CA2291709A1 (en) * 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
NL1010018C2 (nl) 1997-09-09 1999-03-10 Duphar Int Res Chinoline en chinazoline derivaten met corticotropine releasing factor (CRF) antagonistische werking.
US6380203B1 (en) 1998-01-14 2002-04-30 Merck & Co., Inc. Angiogenesis inhibitors
IL137019A0 (en) * 1998-01-28 2001-06-14 Du Pont Pharm Co Azolo triazines and pyrimidines
WO1999045007A1 (en) * 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Crf antagonistic pyrazolo[4,3-b]pyridines
EP1068205A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino 2,3-b]indole and 5,6,7,8-tetrahydro-9h-pyrimidino 4,5-b]indole derivatives: crf1 specific ligands
US6472402B1 (en) 1998-04-02 2002-10-29 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-Tetrahydro-9H-Pyridino [2,3-B]indole derivatives
AU2321000A (en) * 1999-01-29 2000-08-18 Sumitomo Chemical Company, Limited Fat accumulation inhibitory agents
AU4331500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
PL354675A1 (en) 1999-09-30 2004-02-09 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
KR20030016222A (ko) * 2000-02-14 2003-02-26 니뽄 다바코 산교 가부시키가이샤 수술후 스트레스 예방ㆍ치료제
US6888004B2 (en) 2001-01-26 2005-05-03 Bristol-Myers Squibb Company Imidazolyl derivatives as corticotropin releasing factor inhibitors
TWI312347B (en) 2001-02-08 2009-07-21 Eisai R&D Man Co Ltd Bicyclic nitrogen-containing condensed ring compounds
BR0209252A (pt) 2001-04-27 2004-07-20 Eisai Co Ltd Pirazolo[1,5-a]piridinas e medicamentos contendo as mesmas
US6872827B2 (en) 2002-04-26 2005-03-29 Chembridge Research Laboratories, Inc. Somatostatin analogue compounds
US7161003B1 (en) * 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7176216B2 (en) 2002-10-22 2007-02-13 Eisai Co., Ltd. 7-phenylpyrazolopyridine compounds
AU2003275589B2 (en) 2002-10-22 2009-05-28 Eisai R & D Management Co., Ltd. 7-phenyl pyrazolopyridine compounds
RS20050532A (sr) 2003-01-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
KR20060056944A (ko) 2003-07-14 2006-05-25 아레나 파마슈티칼스, 인크. 대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
US20070293511A1 (en) * 2003-12-22 2007-12-20 Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation Crf Receptor Antagonists and Methods
JP4926720B2 (ja) * 2003-12-22 2012-05-09 スミスクライン ビーチャム （コーク） リミテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
JP2008503444A (ja) * 2004-02-13 2008-02-07 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド Ｃｒｆ受容体アンタゴニスト、その調製法、その医薬組成物およびその使用
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
ATE512966T1 (de) 2005-02-11 2011-07-15 Hoffmann La Roche Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
CN101142217B (zh) * 2005-03-21 2010-12-08 伊莱利利公司 咪唑并哒嗪化合物
PT1863818E (pt) 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
US7557103B2 (en) 2005-04-05 2009-07-07 Eli Lilly And Company Imidazopyridazine compounds
EP1922321A1 (en) * 2005-08-09 2008-05-21 Eirx Therapeutics Ltd Pyrazoloý1,5-a¨pyrimidine compounds and pharmaceutical compositions containing them
ATE463495T1 (de) 2005-09-27 2010-04-15 Hoffmann La Roche Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
KR101088239B1 (ko) 2006-09-20 2011-11-30 일라이 릴리 앤드 캄파니 Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
MX2009003098A (es) 2006-09-20 2009-04-01 Lilly Co Eli Compuestos de tiofen pirazolopirimidina.
KR101150581B1 (ko) 2007-07-26 2012-06-11 노파르티스 아게 유기 화합물
MY152687A (en) 2008-04-15 2014-10-31 Eisai R&D Man Co Ltd 3-phenylpyrazolo[5,1-b]thiazole compound
AR078521A1 (es) 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
CN103221410B (zh) 2010-09-22 2017-09-15 艾尼纳制药公司 Gpr119受体调节剂和对与其相关的障碍的治疗
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
CA3002540C (en) 2015-01-06 2023-11-07 Arena Pharmaceuticals, Inc. Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
PL236355B1 (pl) * 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
JP6838744B2 (ja) 2015-06-22 2021-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
IL311645B2 (en) 2016-07-12 2025-11-01 Revolution Medicines Inc 2,5- disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines asallosteric shp2 inhibitors
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
CN110446709B (zh) 2017-01-23 2023-09-12 锐新医药公司 作为变构shp2抑制剂的二环化合物
BR112020002967A2 (pt) 2017-08-14 2020-08-11 Spruce Biosciences, Inc. antagonistas de receptor de fator de liberação de corticotropina
TWI803504B (zh) * 2017-08-14 2023-06-01 美商雲杉生物科技股份有限公司 促皮質素釋放因子受體拮抗劑
TWI852912B (zh) 2017-09-07 2024-08-21 美商銳新醫藥公司 Shp2抑制劑組合物以及治療癌症的方法
BR112020007058A2 (pt) 2017-10-12 2020-10-06 Revolution Medicines, Inc. compostos de piridina, pirazina, e triazina como inibidores de shp2 alostéricos
BR112020009757A2 (pt) 2017-12-15 2020-11-03 Revolution Medicines, Inc. compostos policíclicos como inibidores alostéricos de shp2
MX2020011344A (es) 2018-04-27 2021-02-09 Spruce Biosciences Inc Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
JP7397011B2 (ja) 2018-06-06 2023-12-12 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を治療する方法
JP2023537598A (ja) 2020-08-12 2023-09-04 スプルース バイオサイエンシーズ，インク． 多嚢胞性卵巣症候群を処置するための方法および組成物
US11708372B2 (en) 2021-11-19 2023-07-25 Spruce Biosciences, Inc. Crystalline composition of tildacerfont and methods of use and preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4211753Y1 (tr) * 1964-06-06 1967-06-30
JPS6157587A (ja) * 1984-08-29 1986-03-24 Shionogi & Co Ltd 縮合複素環誘導体および抗潰瘍剤
JPH0211753A (ja) * 1988-06-29 1990-01-16 Raimuzu:Kk ＴｉＡｌ系複合部材及びその製造方法
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines

Also Published As

Publication number Publication date
ATE336495T1 (de) 2006-09-15
EE04282B1 (et) 2004-04-15
EE9800124A (et) 1998-10-15
DE880523T1 (de) 2002-07-04
JP2002121194A (ja) 2002-04-23
IL123835A0 (en) 1998-10-30
EA199800394A1 (ru) 1998-10-29
BR9707391A (pt) 1999-07-20
DK0880523T3 (da) 2007-03-26
KR100421626B1 (ko) 2004-05-20
ES2168237T1 (es) 2002-06-16
CZ244598A3 (cs) 1998-10-14
AU713673B2 (en) 1999-12-09
SK106398A3 (en) 1998-12-02
HUP9900575A2 (hu) 1999-06-28
EP0880523B1 (en) 2006-08-16
CA2233285C (en) 2006-07-04
PT880523E (pt) 2007-01-31
AR008577A1 (es) 2000-02-09
NZ330119A (en) 2000-02-28
DE69736513T2 (de) 2007-04-05
TW449599B (en) 2001-08-11
KR19990067391A (ko) 1999-08-16
EA000803B1 (ru) 2000-04-24
EP0880523A1 (en) 1998-12-02
JP2000503661A (ja) 2000-03-28
CA2233285A1 (en) 1997-08-14
JP3356291B2 (ja) 2002-12-16
AU1599197A (en) 1997-08-28
ID15905A (id) 1997-08-14
BG102349A (en) 1999-02-26
WO1997029109A1 (en) 1997-08-14
CN1205009A (zh) 1999-01-13
DE69736513D1 (de) 2006-09-28
NO981357L (no) 1998-08-03
PL327284A1 (en) 1998-12-07
NO310292B1 (no) 2001-06-18
NO981357D0 (no) 1998-03-25
CN1090189C (zh) 2002-09-04
HUP9900575A3 (en) 2001-11-28
ES2168237T3 (es) 2007-04-01
PL191271B1 (pl) 2006-04-28

Similar Documents

Publication Publication Date Title
BG102349A (en) Pyrazolopyrimidines as crf receptor antagonists
TW376385B (en) Watersoluble azole antifungals
CA2264721A1 (en) A1 adenosine receptor antagonists
MX9700883A (es) Derivados sustituidos de la quinazolina.
TR200101893T2 (tr) Antiviral maddeler olarak 4-okso-1,4 dihidro -3- kuinolinkarboksamitler.
TR199902203T2 (tr) Fernesil transferaz engelleyici, N-veya C-baglantili imidazoller ile ikame edilmis 1,8-anele kinolinon türevleri.
ATE25682T1 (de) Indol-3-carboxamid-derivate.
HUP0002330A2 (hu) Azetidinilpropilpiperidin-származékok, ezek intermedierjei és tachikinin antagonistaként történő alkalmazásuk
BG104933A (en) Water soluble azoles and broad-spectrum antifungals
ES2142773A1 (es) Derivados de mononitrato de isosorbida y su empleo como agentes vasodilatadores con tolerancia desminuida.
ES2175328T3 (es) Piperidonas como antagonistas de la taquiquinina.
JPS6422813A (en) Antiphlegmonic slimming cosmetics containing 1-hydroxyalkylxanthin
AU672448B2 (en) Antiretroviral hydrazine derivatives
IL136911A0 (en) Heterocyclic topoisomerase poisons
CA2117610A1 (en) Indole derivatives as steroid 5 alpha-reductase inhibitors
TNSN04121A1 (en) Acides 3 - (imidazolyl) - 2 - alkoxypropanoiques servant d'inhibiteurs de tafia
DE69910574D1 (de) Pyrazolo[1,5-a]triazine als crf antagonisten
GB9720270D0 (en) Medicaments for the treatment of migraine
ATE229538T1 (de) 22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
DE60144246D1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
ES2159489A1 (es) Nuevos derivados de imidazol con actividad antiinflamatoria.
BR0007544A (pt) Uso de um peróxido de diacila em combinação com uma amina aromática, processo para a preparação de grânulos de poliéster sólidos, e, grânulos de poliéster sólidos
MY121785A (en) Hydroxamic acid derivatives as inhibitors of the production of soluble cd23
BR9508979A (pt) Carboxamidas bicíclicas como antagonistas de 5-ht1a
GB1472869A (en) Intermediates for cephalosporin synthesis